Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Lists including Mark
Investments
Evommune
Total Funding: $150M
Ensoma
Total Funding: $210M
Disc Medicine
Total Funding: $440M
VelosBio
Total Funding: $200M
Imara
Total Funding: $63M
Harpoon Therapeutics
Total Funding: $120M
Aura Biosciences
Total Funding: $130M
Iterum Therapeutics
Total Funding: $110M
Work Experience
2023
Partner
2023
Biotech investment firm focused on early, mid, and late-stage private companies
2021 - 2023
Managing Director
2021 - 2023
Biotech venture capital firm focused on early, mid, and late-stage private and small-cap public companies
2016 - 2020
Investment Director
2016 - 2020
Biotech venture capital firm focused on early, mid, and late-stage private companies Notable deals include: VelosBio (acquired by Merck for $2.75b): Co-led Series A financing Imara (IMRA): Co-led Series B financing Harpoon Therapeutics (HARP): Co-led Series B financing Aura Biosceinces: Co-led Series C financing
2012 - 2016
Principal
2012 - 2016
Life sciences investment firm that focuses on venture growth investments in drug development and medical technology
2011 - 2012
Consultant
2011 - 2012
Healthcare practice with an emphasis in early-stage biotechnology and pharmaceuticals
2010 - 2010
Corporate Development
2010 - 2010
2009 - 2009
Market Planning
2009 - 2009
BioOncology Pipeline Market Planning for T-DM1
2006 - 2008
Manager
2006 - 2008
Life sciences strategy consulting firm focused on pharmaceutical, biotechnology, and private equity clients
2004 - 2006
Senior Business Analyst
2004 - 2006
Financial services strategy consulting firm focused on banks, insurers, and private equity clients
2004 - 2004
Analyst
2004 - 2004